EN SV Investors At Sobi, we are transforming the lives of people affected by rare diseases. We are providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. More information about the offer by Advent and GIC, through Agnafit Bidco Link to Agnafit Bidco AB’s web site Link to Sobi’s press release RESULTS CENTRE Interim Report Q3 2021 'We saw continued growth and pipeline progress in the third quarter of 2021, and it is satisfying to see that results are confirming our strategic direction. ' GUIDO OELKERS, CEO AND PRESIDENT REPORT Capital Markets Day 2020 The Capital Markets Day 2020 was held on Thursday 10 December 2020. FIND OUT MORE WEBCAST REPORTS & PRESENTATIONS Annual report 2020 DOWNLOAD PDF SHARE PRICE Loading... SHARE INFORMATION UPCOMING EVENTS Loading... FINANCIAL CALENDAR EMAIL ALERT Sign up for Sobi press releases SIGN UP FINANCIAL DATA Key figures EXPLORE INVESTOR CONTACTS Thomas Kudsk Larsen Head of Communication and Investor Relations thomas.kudsklarsen@sobi.com +44 7443 191 773 Maria Kruse Director Corporate Communications & Investor Relations maria.kruse@sobi.com +46 767 24 88 30 Jörgen Winroth Senior IR Advisor jorgen.winroth@sobi.com +1 347 224 0819 About us At a glance Rare diseases Therapeutic areas Haematology Immunology Specialty Care portfolio Investors Reports & presentations Share information Calendar Career Open positions Meet our employees Media Press releases Gallery Sobiplay Sitemap Cookie Policy Privacy Policy Terms of use Cookies Settings © Swedish Orphan Biovitrum AB (publ) Reg. no. 556038-9321